Market Cap
$297.68M
Shares Outstanding
147.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 8, 2017
Round Lot
100
Locale
US
Day Open
$2.02
Day High
$2.07
Day Low
$1.99
Volume
567.1K
VWAP
$2.00
Prev Close
$2.02
Transactions
--
Acc. Volume
--
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
InflaRx N.V. Common Stock (IFRX) closed the 2026-09-16 session at $2.00, down 0.74% versus the previous close (-0.02). The stock opened at $2.02 and traded between $1.99 and $2.07 during that session. Session trading volume was 567K shares. The volume-weighted average price (VWAP) is $2.00.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
InflaRx N.V. Common Stock has a market capitalization of $297.7 million. IFRX is listed on the XNAS exchange. The company employs approximately 65 people. The recorded listing date is 2017-11-08.
On this page you can find market IFRX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.